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Romidepsin enhances the efficacy of cytarabine 
in vivo, revealing histone deacetylase inhibition as a
promising therapeutic strategy for 
KMT2A-rearranged infant acute lymphoblastic
leukemia
Acute lymphoblastic leukemia (ALL) in infants diag-
nosed at less than 12 months of age is an aggressive malig-
nancy with a poor prognosis. Rearrangements of the
KMT2A gene (KMT2A-r) are present in up to 80% of
cases, with 5-year event-free survival (EFS) less than 40%.1
Dose intensive chemotherapy has been incorporated into
contemporary treatment regimens; however, this has
increased the burden of toxicity during therapy and late
effects in survivors.1,2 There is a desperate need to identify
novel therapies to improve outcome.
Histone deacetylase inhibition appears to be a promising
therapeutic strategy for KMT2A-r infant ALL, with our
recent chemo-genomic profiling identifying the potential
for romidepsin. Romidepsin was shown to enhance the in
vitro activity of cytarabine, a key component of infant ALL
therapy, with an in vivo signal identified when combined
with high-dose cytarabine.3 In this study, we investigate
the in vivo synergy between romidepsin and cytarabine,
determine the in vivo toxicity of this combination, and fur-
ther explore the effect of romidepsin on the DNA damage-
response to cytarabine. All in vivo experiments were
approved by the Animal Ethics Committee, Telethon Kids
Institute, Perth, Australia.
To determine drug toxicity and efficacy upon comple-
tion of therapy, 7-week old female NOD/SCID mice were
inoculated with 1x106 PER-785A cells. PER-785A is a
genetically characterized cell line harboring the t(4;11)
translocation.3 For all in vivo studies, drug treatment was
commenced when the percentage of human CD19+ or
CD45+ cells reached 1% in the bone marrow (BM), identi-
fied from extensive mapping of the leukemia cell kinetics
for each model (Online Supplementary Figure S1). Treatment
was scheduled to mimic the concepts of contemporary
clinical trial design. Currently, novel agents are being
investigated following induction therapy on the Interfant
chemotherapy backbone,4 thus are introduced in the set-
ting of low disease burden rather than at diagnosis where
overt disease is evident in the BM. Mice were randomized
into five groups of five mice and drug treatment was com-
menced on day 12 by intraperitoneal (i.p.) injection.
Treatment groups comprised of vehicle control; 1.5 mg/kg
romidepsin twice/week on Mondays and Thursdays; low-
dose cytarabine (5 mg/kg) five times/week Monday to
Friday; high-dose cytarabine (100 mg/kg) five times/week
Monday to Friday; combination therapy with 1.5 mg/kg
romidepsin and low-dose cytarabine. Treatment was
administered for three weeks. Three days following com-
pletion of therapy mice were sacrificed and leukemia bur-
den was determined by measuring the percentage of
human CD19+ cells in the BM by flow cytometry with
anti-human CD19-APC antibody. At the time of sacrifice,
0.2 mL of blood was obtained from each mouse by cardiac
puncture and a complete blood count  performed to deter-
mine the degree of myelosuppressive toxicity for each
cohort. Single-agent activity was observed with the mean
percentage of leukemic cells in the BM of 66.6% (P<0.01)
for romidepsin and 27.3% (P<0.01) for low-dose cytara-
bine (Figure 1A). The reduction in leukemic burden was
significantly enhanced with combination therapy with a
reduction to a mean of 3.8% infiltration (P<0.0001) (Figure
1A). Although treatment with high-dose cytarabine
achieved clearance of leukemic cells from the BM, mice
treated with high-dose cytarabine developed severe
myelosuppression in comparison to the other cohorts
(Figure 1B). In particular, there was a statistically signifi-
cant reduction in mean hemoglobin (98 vs. 42.5 g/L;
P<0.0001), white blood cell (2.43 vs. 0.13x109/L;
P<0.0001) and platelet (757 vs. 294x109/L; P<0.0021)
count between the mice treated with romidepsin and low-
dose cytarabine combination therapy compared to those
treated with high-dose cytarabine.
Three xenograft models, PER-785, MLL-5 and MLL-14,
were used to determine the response to drug treatment by
EFS. MLL-5 and MLL-14 are well characterized patient-
derived xenografts which harbor t(10;11) and t(11;19)
translocations respectively.5 MLL-5 and MLL-14 were
selected to test whether findings could be validated in
independent models with distinct translocation partners.
For MLL-5, drug treatment commenced 11 days following
injection of 1x106 cells, and for MLL-14, treatment com-
menced seven days following injection of 2x106 cells, cor-
responding to 1% of human CD45+ cells in the BM. For
each xenograft model, mice were randomized into four
groups of eight mice prior to commencing therapy by i.p.
injection. Given that the premise was to identify novel
agents that would abrogate the toxicity of conventional
chemotherapeutic agents, high-dose cytarabine was not
further investigated. The rest of the treatment groups and
schedules remained the same. Individual mouse EFS was
calculated as the time in days from treatment initiation
until mice reached a humane end point with evidence of
leukemia-related morbidity. For MLL-5 and MLL-14, the
anti-human CD45-PE antibody was used to determine the
percentage of human CD45+ cells by flow cytometry. EFS
curves were compared using log-rank test. 
Compared to vehicle control, a significant survival ben-
efit was seen with low-dose cytarabine alone for PER-785
and MLL-5 but not for MLL-14 (Figure 1C and Online
Supplementary Table S1). This finding of differential sensi-
tivity to cytarabine was validated in vitro (Online
Supplementary Table S2). Our models thus provide repre-
sentation of the known inter-patient variability in
response to conventional chemotherapeutic agents. A sig-
nificant survival advantage was not demonstrated for
romidepsin monotherapy; however, combination therapy
with romidepsin and low-dose cytarabine resulted in a
profound and highly significant increase in median sur-
vival in all three xenograft models, compared to both vehi-
cle control and low-dose cytarabine alone (Figure 1C and
Online Supplementary Table S1). As expected, at the time
the mice succumbed to leukemia, the disease burden was
similar in all treatment groups (Online Supplementary Figure
S2).
Next, we determined whether romidepsin enhanced the
DNA-damage response of cytarabine in six of our previ-
ously characterized infant ALL cell lines.3 Phospho-H2A.X
levels were determined by flow cytometry and western
blotting (Online Supplementary Methods). For all cell lines,
romidepsin was shown to significantly enhance the DNA
double-strand break response of cytarabine (Figure 2A and
B and Online Supplementary Figure S3). However, between
cell lines there was variability in the extent to which DNA-
damage was enhanced; this may reflect a potential for dif-
ferences in the magnitude of clinical effect between
patients. Romidepsin was not shown to increase the
expression of other components of the DNA-damage sig-
naling pathway (Online Supplementary Figure S4) or
increase the inhibition of DNA repair (Online
Supplementary Figure S5) when combined with cytarabine. 
Using our panel of infant ALL cell lines, we subsequent-
ly determined whether romidepsin exhibited synergy with
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other conventional agents used in the Interfant
chemotherapy backbone. In vitro synergy experiments
were performed as previously described, with synergy
scored using Chalice software, applying the Bliss-indepen-
dence model.3 Synergy was demonstrated across all six cell
lines for romidepsin combined with daunorubicin or 4-
hydroperoxycyclophosphamide (Table 1). Romidepsin
was also shown to significantly enhance the DNA double-
strand break response of daunorubicin and 4-hydroperox-
ycyclophosphamide at the protein level (Figure 2C and D).
Mixed responses across the cell line panel were observed
when romidepsin was combined with vincristine (synergy
in four cell lines) or dexamethasone (synergy in three cell
lines), whereas antagonism was observed in four out of six
cell lines when romidepsin was combined with
methotrexate or 
L-asparaginase (Table 1). Our data provide support for
romidepsin to be scheduled prior to or during cytarabine-
and cyclophosphamide-based therapy within the current
standard Interfant chemotherapy backbone, namely pro-
tocol IB and the second half of OCTADAD. 
There is a desperate need to identify novel agents for
integration into up-front therapy to improve the dismal
outcome of infants with KMT2A-r ALL. The 
KMT2A-fusion protein has altered histone-methyltrans-
ferase activity with characteristic changes to chromatin
and transcriptome.6 Several components of the KMT2A-
complex can be targeted by novel agents. However, in
order to integrate any novel drug into infant therapy pro-
tocols, the drug needs to be available in a preparation suit-
able for administration to infants, i.e. as an oral suspension
or formulated for intravenous use. Furthermore, current
infant ALL protocols contain up to ten different
chemotherapeutics, given in an intricate drug delivery
scheme over 24 months. Evidence is required as to where
in the standard chemotherapy backbone novel drugs can
be safely administered with maximal effect. Simultaneous
administration with a conventional chemotherapeutic
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Figure 1. Romidepsin and low-dose cytarabine combination therapy reduces leukemia bur-
den and improves survival in mice. (A and B) Mice injected with PER-785 leukemia cells
were treated with vehicle control, 1.5 mg/kg romidepsin (ROM) twice weekly, low-dose (5
mg/kg) cytarabine (AraC) five times a week, high-dose (100 mg/kg) AraC five times a week,
or a combination of 1.5 mg/kg ROM and low-dose AraC for three weeks. Mice were sacri-
ficed three days following completion of therapy (n=4-5 mice/group). (A) Leukemia burden
in the bone marrow and (B) Complete blood count measurements. (C) Kaplan-Meier survival
curves of mice injected with PER-785, MLL-5, or MLL-14 leukemia cells that were treated
with vehicle control, 1.5 mg/kg ROM, 5 mg/kg AraC, or combination of 1.5 mg/kg ROM and
5 mg/kg AraC for three weeks (n=7-8 mice/group). Two-tailed unpaired Student t-test was
used to analyze leukemia burden and complete blood count measurements, and log-rank
test for Kaplan-Meier survival analysis. Error bars represent mean±Standard Deviation.
**P<0.01; ***P<0.001; ****P<0.0001. 
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Figure 2. Romidepsin enhances the DNA double-strand break response of DNA damaging chemotherapeutic agents. (A and B) Leukemia cell lines were treated
with 2 nM romidepsin (ROM), 1 mM cytarabine (AraC), or combination of 2 nM ROM and 1 mM AraC for 24 hours (h). (A) Cells were stained with PI and phospho-
H2A.X and analyzed by flow cytometry. (B) Western blot analysis of phospho-H2A.X protein levels in the treated cell lines (left). Bar graphs depict phospho-
H2A.X/b-actin densitometry ratios that were normalized to ratios calculated for non-treated controls (right). (C) Leukemia cell lines were treated with 2 nM ROM,
30 nM Daunorubicin (DNR), or combination of 2 nM ROM and 30 nM DNR for 24 h. (D) Leukemia cell lines were treated with 2 nM ROM, 2 mM 4-hydroperoxy-
cyclophosphamide (4HPC), or combination of 2 nM ROM and 2 mM 4HPC for 24 h. (C and D) Western blot analysis of phospho-H2A.X protein levels in the treated
cell lines (top). Bar graphs depict phospho-H2A.X/b-actin densitometry ratios that were normalized to ratios calculated for non-treated controls (bottom). Data
were collected from three independent experiments and analyzed using the two-tailed unpaired Student t-test. Error bars represent mean±Standard Deviation.
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
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agent would only be considered for clinical use if the drug
combination achieves more than each drug individually,
with a tolerable toxicity profile, and if antagonism can be
excluded. Our study focused on KMT2A-r infant ALL;
however, use of romidepsin is not specific for this indica-
tion, with current extensive clinical investigation in com-
bination regimens for several adult hematologic malignan-
cies, including anthracycline based-therapies, ICE (ifos-
famide, carboplatin and etoposide) and gemcitabine-con-
taining regimens.7Our study provides strong evidence that
romidepsin can be combined to augment the effect of the
conventional chemotherapeutic agent, cytarabine, in
infants with KMT2A-r ALL without undue myelosuppres-
sion, which is one of the predominant dose-limiting side
effects of chemotherapy. The potential for histone
deacetylase inhibition in ALL has also been highlighted in
several recent studies,8-10 including strong in vivo efficacy of
panobinostat against human KMT2A-r ALL.8 Taken
together, there is mounting evidence to support the use of
histone deacetylase inhibitors in the next generation of
clinical trials for infants with KMT2A-r ALL.
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Table 1. Total and maximum in vitro synergy scores between romidepsin and conventional chemotherapy agents.
